刘晓强;杨海涛;李海燕;双慧;张丽芬;杨双敏;沈红杰;栾鸣;苏畅;汝东宇;

• 1:云南省疾病预防控制中心
• 2:长春祈健生物制品有限公司
• 3:大理大学

摘要(Abstract)：

目的通过与已上市同类疫苗比较,评价在≥13岁健康人群中接种2剂次国产水痘减毒活疫苗(VarV)的免疫原性和安全性。方法采用单中心、随机、双盲、同类疫苗对照的非劣效性试验设计,在云南省某县选择1 200名≥13岁健康人群,随机分为试验组和对照组,按0、42d免疫程序分别接种2剂次试验疫苗和对照疫苗(对照疫苗为另一种已上市的国产VarV),检测受试者免疫前和免疫后30d血清水痘中和抗体,观察免疫后1年内的不良事件,比较两组水痘抗体水平和不良事件发生率。结果试验组、对照组接种2剂次VarV后水痘抗体阳转/≥4倍增长率分别为72.41%(433/598)、71.79%(430/599)(Fisher确切概率法,P=0.811),率差为0.62%(95%CI:-4.46%-5.70%)。两组总不良事件发生率分别为28.93%(173/598)、30.22%(181/599)(Fisher确切概率法,P=0.658)。结论本研究≥13岁健康人群国产VarV中2剂次免疫程序具有良好的免疫原性和安全性,非劣于对照疫苗。

关键词(KeyWords)： 水痘减毒活疫苗;免疫原性;安全性

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 刘晓强;杨海涛;李海燕;双慧;张丽芬;杨双敏;沈红杰;栾鸣;苏畅;汝东宇;

Email:

DOI:

参考文献(References)：

• [1]梁慧颖,邹勇.冻干水痘减毒活疫苗发展现状及趋势[J].中国新药杂志,2012,21(10):1076-1079+1161.LIANG Huiying,ZOU Yong.Development status and trend offreeze dried live attenuated varicella vaccine[J].Chinese Journal ofNew Drugs,2012,21(10):1076-1079+1161.
• [2]杨绍基.传染病学[M].7版.北京:人民卫生出版社,2008:65-66.YANG Shaoji.Infectious diseases[M].7 edition.Beijing:People's Medical Publishing House,2008:65-66.
• [3]金连梅,冯子健.2005-2006年全国水痘疫情分析[J].疾病监测,2007,22(4):251-252+255.JIN Lianmei,FENG Zi jian.Analysis ofthe epidemic situation ofchicken pox from 2005 to 2006 in China[J].Disease Surveillance,2007,22(4):251-252+255.
• [4]Diseases C O I.Prevention ofvaricella:recommendations for use ofvar icel la vaccines in chi ldren,including a r ecommendation for aroutine 2-dose va r icel la immunization schedule(2007)[J].Pediatrics,2007,120(1):221-231.
• [5]WHO.Varicella and herpes zoster vaccines:WHO position paper,June 2014[J].WER,2014,89(25):265-288.
• [6]杨洁,黄芳,林喜乐.水痘减毒活疫苗两针法免疫效果及安全性评价[J].现代预防医学,2015,42(14):2630-2632.YANG Jie,HUANG Fang,LIN Xile.Immune effect and safety evaluation on the two-dose schedule for live attenuated var icella vaccine[J].Modern Prevent ive Medicine,2015,42(14):2630-2632.
• [7]陶航.水痘疫苗免疫策略研究[D].长春:吉林大学,2015.TAO Hang.The study on immunizat ion st rategy ofvaricella vaccine[D].Changchun:Jilin University,2015.
• [8]MICHALIK DE,STEINBERG SP,LARUSSA PS,et al.Primary vaccine failure after 1 dose ofvaricella vaccine in healthy children[J].The Journal ofInfectious Diseases,2008,197(7):944-949.
• [9]CHAVES S,GARGIULLO PJ,CIVEN R,et al.Loss ofvaccine-induced immunity to varicella over time[J].The New England Journal ofMedicine,2007,356(11):1121-1129.
• [10]何蔚云.儿童集体单位水痘暴发与水痘疫苗接种效果的病例对照研究[D].广州:南方医科大学,2012.HE Weiyun.A case-control study on the effectiveness ofvar icella vaccine dur ing outbreaks in schools and kinde rga r t e n s[D].Gua ngzhou:Sout he r n Medica l University,2012.
• [11]许国章.水痘及其免疫预防研究进展[J].中国计划免疫,2002,8(1):54-58.XU Guozhang.Progress in chicken pox and its immunological prevention[J].Chinese Journal ofVaccines and Immunology,2002,8(1):54-58.
• [12]钱晓华,谭顺荣,杨彦基,等.单剂水痘疫苗接种后人群中暴发水痘疫情的原因分析[J].中国生物制品学杂志,2012,25(11):1527-1529+1534.QIAN Xiaohua,TANG Shunrong,YANG Yan ji,et al.Reason for outbreak ofvar icella in populat ion after immunization with a single dose ofvaricella vaccine[J].Chinese Journal ofBiologicals,2012,25(11):1527-1529+1534.
• [13]GERSHON AA,STEINBERG SP,LARUSSA P,et al.Immunizat ion ofheal thy adul ts with live attenuated varicella vaccine[J].The Journal ofInfectious Diseases,1988,158(1):132-137.
• [14]王群,李彦成,王立成.1~6岁儿童接种冻干水痘减毒活疫苗安全性和免疫原性观察[J].预防医学,2017,29(7):711-713.WANG Qun,LI Yancheng,WANG Licheng.Observation on safety and immunogenicity of1~6 year old children inocula ted wi th va r icel la vaccine freeze-dr ied[J].Preventive Medicine,2017,29(7):711-713.
• [15]殷大鹏.中国水痘疫苗免疫策略评价和成本效益分析[D].北京:中国疾病预防控制中心,2012.YIN Dapeng.The immunization strategy evaluation and cost-benefit analysis ofvaricella attenuated live vaccine in China[D].Beijing:Chinese Center for Disease Control and Prevention,2012.